

AMENDMENTS TO THE CLAIMS

This listing of claims replaces all previous versions, and listings, of claims pending in this application.

Listing of Claims

This listing of claims replaces all previous versions, and listings, of claims pending in this application.

Listing of Claims

1-161. (Canceled)

162. (Currently amended) A compound comprising a peptide chain having a sequence of amino acids $CX^{IV}_1X^{IV}_2X^{IV}_3X^{IV}_4X^{IV}_5X^{IV}_6X^{IV}_7X^{IV}_8X^{IV}_9X^{IV}_{10}C$ that binds to a G-CSFR, wherein said sequence of amino acids is selected from the group consisting of GGGLLDICELKLQECARRCN (SEQ ID NO: 209); GRTGGLLDICELKLQECARRCN (SEQ ID NO: 210); LGIEGRTGGGLLDICELKLQECARRCN (SEQ ID NO: 211); ~~LLDICEELKLQEAARRCN~~ and LLDICELKLQEAARRCN (SEQ ID NO: 212); ~~LLDIAELKLQECARRCN (SEQ ID NO: 464); and LLDICELKLQECARRAN (SEQ ID NO: 343),~~ and wherein each amino acid is indicated by standard one-letter abbreviation.

163. (Previously presented) The compound of claim 162, wherein said sequence of amino acids is GGGLLDICELKLQECARRCN (SEQ ID NO: 209).

164. (Previously presented) The compound of claim 162, wherein said sequence of amino acids is GRTGGLLDICELKLQECARRCN (SEQ ID NO: 210).

165. (Canceled)

166. (Previously presented) The compound of claim 162, containing a disulfide bond.

167. (Previously presented) The compound of claim 162 wherein the N terminus of the peptide is coupled to a polyethylene glycol molecule.

168. (Previously presented) The compound of claim 162 wherein the N terminus of the peptide is acetylated.

169. (Previously presented) The compound of claim 162, wherein the C terminus of the peptide is amidated.

170. (Previously presented) A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 162, in combination with a pharmaceutically acceptable carrier.

171. (Withdrawn – currently amended) A method for treating a patient who would benefit from administration of a GCSF modulator, comprising administering to the patient a therapeutically effective amount of the compound of any one of claims 162, 179, and 180. ~~claim 162.~~

172. (Withdrawn) The method of claim 171, wherein the G-CSF modulator is an agonist for the GCSFR.

173. (Withdrawn) The method of claim 171, wherein the patient suffers from a depressed neutrophil count.

174. (Withdrawn) The method of claim 173, wherein the depressed neutrophil count is associated with a condition selected from the group consisting of chemotherapy-induced neutropenia, AIDS induced neutropenia and community-acquired pneumonia-induced neutropenia.

175. (Previously presented) The compound of claim 162, wherein said sequence of amino acids is LGIEGRTGGGLLDICELKLQECARRCN (SEQ ID NO: 211).

176. (Currently amended) The compound of claim 162, wherein said sequence of amino acids is LLDICEELKLQEAARRCN LLDICELKLQEAARRCN (SEQ ID NO: 212).

177-178. (Canceled)

179. (New) A compound comprising a peptide chain having a sequence of amino acids $X^{\text{VI}}_1X^{\text{VI}}_2X^{\text{VI}}_3X^{\text{VI}}_4X^{\text{VI}}_5EX^{\text{VI}}_6X^{\text{VI}}_7X^{\text{VI}}_8X^{\text{VI}}_9$ that binds to a G-CSFR, wherein said sequence of

amino acids is LLDIAELKLQECARC� (SEQ ID NO:464), and wherein each amino acid is indicated by standard one-letter abbreviation.

180. (New) A compound comprising a peptide chain having a sequence of amino acids $X^V_1X^V_2X^V_3X^V_4X^V_5X^V_6CX^V_7X^V_8$ that binds to a G-CSFR, wherein said sequence of amino acids is LLDICELKLQECARRAN (SEQ ID NO:343), and wherein each amino acid is indicated by standard one-letter abbreviation.

181. (New) The compound of claim 179 or 180, containing a disulfide bond.

182. (New) The compound of claim 179 or 180 wherein the N terminus of the peptide is coupled to a polyethylene glycol molecule.

183. (New) The compound of claim 179 or 180 wherein the N terminus of the peptide is acetylated.

184. (New) The compound of claim 179 or 180, wherein the C terminus of the peptide is amidated.